Amgen’s (AMGN) “Hold” Rating Reaffirmed at BMO Capital Markets
Amgen Inc. (NASDAQ:AMGN)‘s stock had its “hold” rating reaffirmed by stock analysts at BMO Capital Markets in a report released on Monday. They presently have a $199.00 target price on the medical research company’s stock. BMO Capital Markets’ price objective suggests a potential upside of 7.13% from the stock’s previous close.
Other research analysts have also issued research reports about the stock. Oppenheimer Holdings, Inc. set a $189.00 price target on shares of Amgen and gave the stock a “buy” rating in a report on Tuesday, June 13th. Mizuho reaffirmed a “buy” rating and set a $195.00 price objective on shares of Amgen in a research report on Sunday, July 9th. ValuEngine raised shares of Amgen from a “hold” rating to a “buy” rating in a research report on Thursday, July 6th. Jefferies Group LLC reaffirmed a “buy” rating and set a $195.00 price objective on shares of Amgen in a research report on Tuesday, July 11th. Finally, Cann reaffirmed a “buy” rating and set a $203.00 price objective (up previously from $189.00) on shares of Amgen in a research report on Wednesday, July 26th. One investment analyst has rated the stock with a sell rating, twelve have assigned a hold rating, eleven have given a buy rating and two have issued a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $186.14.
Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, July 25th. The medical research company reported $3.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.11 by $0.16. Amgen had a net margin of 35.46% and a return on equity of 29.85%. The firm had revenue of $5.81 billion during the quarter, compared to analyst estimates of $5.67 billion. During the same quarter last year, the business earned $2.84 EPS. The company’s revenue was up 2.1% compared to the same quarter last year.
COPYRIGHT VIOLATION WARNING: “Amgen’s (AMGN) “Hold” Rating Reaffirmed at BMO Capital Markets” was originally reported by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another website, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be accessed at https://www.watchlistnews.com/amgens-amgn-hold-rating-reaffirmed-at-bmo-capital-markets/1585798.html.
A number of institutional investors and hedge funds have recently bought and sold shares of the business. TrimTabs Asset Management LLC raised its stake in shares of Amgen by 88.9% during the 1st quarter. TrimTabs Asset Management LLC now owns 612 shares of the medical research company’s stock worth $100,000 after purchasing an additional 288 shares during the period. Alpha Omega Wealth Management LLC raised its stake in shares of Amgen by 19.0% during the 1st quarter. Alpha Omega Wealth Management LLC now owns 625 shares of the medical research company’s stock worth $103,000 after purchasing an additional 100 shares during the period. Jackson Grant Investment Advisers Inc. raised its stake in shares of Amgen by 0.6% during the 1st quarter. Jackson Grant Investment Advisers Inc. now owns 636 shares of the medical research company’s stock worth $104,000 after purchasing an additional 4 shares during the period. American Beacon Advisors Inc. bought a new stake in shares of Amgen during the 1st quarter worth $106,000. Finally, Phocas Financial Corp. bought a new stake in shares of Amgen during the 2nd quarter worth $110,000. 78.09% of the stock is currently owned by hedge funds and other institutional investors.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.